Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD5 | P21918 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 5/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4220274 | 0.85 | CYP2A6 (0.46) | CYP1A2HTR2ACYP2A6DRD2DRD1 | |
| SCHEMBL4285081 | 0.77 | CYP1A2 (0.48) | CYP1A2HTR2ACYP2A6DRD2DRD1 | |
| SCHEMBL12690128 | 0.72 | CYP1A2 (0.43) | CYP1A2HTR2ACYP2A6DRD2DRD1 | |
| SCHEMBL29392481 | 0.72 | CYP1A2 (0.43) | CYP1A2CYP2A6DRD2DRD1DRD4 | |
| SCHEMBL5190200 | 0.72 | CYP1A2 (0.43) | CYP1A2CYP2A6DRD2DRD1DRD4 | |
| SCHEMBL29881712 | 0.71 | — | — | |
| SCHEMBL109650 | 0.71 | CYP1A2 (0.62) | CYP1A2HTR2ACYP2A6DRD2DRD1 | |
| SCHEMBL22081972 | 0.71 | CYP1A2 (0.62) | CYP1A2HTR2ACYP2A6DRD2DRD1 | |
| SCHEMBL1525601 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL11399645 | 0.70 | IDO1 (0.40) | CYP1A2HTR2ACYP2A6DRD2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895306-B2 | Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895306-B2 | Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895306-B2 | Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2014-11-25 | — | — | US | disclosed |
| US-8669072-B2 | Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2014-03-11 | — | — | US | disclosed |
| US-8669072-B2 | Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2014-03-11 | — | — | US | disclosed |
| US-8669072-B2 | Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2014-03-11 | — | — | US | disclosed |
| EP-1601354-B1 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2013-11-13 | — | — | EP | disclosed |
| EP-1601354-B1 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2013-11-13 | — | — | EP | disclosed |
| EP-1601354-A4 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20090149514-A1 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORPORATION | 2009-06-11 | — | — | US | disclosed |
| US-20080255210-A1 | 1-Benzyl-3-[3-(3,5-dimethyl-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-urea; nuclear receptor-based inducible gene expression system | HORMANN ROBERT EUGENE | 2008-10-16 | — | — | US | disclosed |
| US-20070287731-A1 | 1-Benzyl-3-[3-(3,5-dimethyl-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-urea; nuclear receptor-based inducible gene expression system | RHEOGENE, INC. (DE CORPORATION) | 2007-12-13 | — | — | US | disclosed |
| US-20070287731-A1 | 1-Benzyl-3-[3-(3,5-dimethyl-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-urea; nuclear receptor-based inducible gene expression system | RHEOGENE, INC. (DE CORPORATION) | 2007-12-13 | — | — | US | disclosed |
| US-20070287731-A1 | 1-Benzyl-3-[3-(3,5-dimethyl-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-urea; nuclear receptor-based inducible gene expression system | RHEOGENE, INC. (DE CORPORATION) | 2007-12-13 | — | — | US | disclosed |
| US-7304162-B2 | Regulating and tailoring expression levels; such as N-[3-(4-chloro-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-3-ethyl-benzamide | INTREXON CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304162-B2 | Regulating and tailoring expression levels; such as N-[3-(4-chloro-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-3-ethyl-benzamide | INTREXON CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304162-B2 | Regulating and tailoring expression levels; such as N-[3-(4-chloro-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-3-ethyl-benzamide | INTREXON CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| EP-1601354-A2 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RheoGene Holdings Inc. (US) | 2005-12-07 | — | — | EP | disclosed |
| WO-2005017126-A2 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE HOLDINGS, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20040171651-A1 | Regulating and tailoring expression levels; such as N-[3-(4-chloro-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-3-ethyl-benzamide | RHEOGENE, INC. (DE CORPORATION) | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287731-A1 | 1-Benzyl-3-[3-(3,5-dimethyl-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-urea; nuclear receptor-based inducible gene expression system | NR0B1, NR0B2, NR5A2 | CYP1A2 2167/4885HTR2A 2773/4885CYP2A6 1405/4885 |
| US-20080255210-A1 | 1-Benzyl-3-[3-(3,5-dimethyl-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-urea; nuclear receptor-based inducible gene expression system | NR0B1, NR0B2, NR5A2 | CYP1A2 2167/4885HTR2A 2773/4885CYP2A6 1405/4885 |
| US-20040171651-A1 | Regulating and tailoring expression levels; such as N-[3-(4-chloro-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-3-ethyl-benzamide | NR2E3, ESRRB, NR0B2 | CYP1A2 2967/4885HTR2A 1780/4885CYP2A6 1528/4885 |
| US-20090149514-A1 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | ESRRB, NR2E3, NR5A1 | CYP1A2 2019/4885HTR2A 2264/4885CYP2A6 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.